Related Experiment Video
Updated: Jun 15, 2026
16:36
Proteomics to Identify Proteins Interacting with P2X2 Ligand-Gated Cation Channels
Published on: May 18, 2009
P2X purinergic receptor ligands: recently patented compounds
Hendra Gunosewoyo1, Michael Kassiou
1University of Sydney, School of Chemistry, NSW 2006, Australia.
Expert Opinion on Therapeutic Patents
|March 9, 2010
Summary
Novel drug-like antagonists targeting P2X receptors (purinergic receptors) show promise for treating inflammation, pain, and depression. Recent patents highlight P2X7 receptor antagonists, with some in clinical trials for conditions like rheumatoid arthritis.
Area of Science:
- Neuroscience
- Pharmacology
- Drug Discovery
Background:
- P2X channels are ionotropic purinergic receptors crucial in the central nervous system (CNS).
- They are recognized as promising therapeutic targets for conditions such as chronic inflammation, pain, and depression.
- Extensive research and patent filings underscore the significance of P2X receptors in medicinal chemistry.
Purpose of the Study:
- To provide a comprehensive review of patent literature on novel drug-like antagonists for P2X receptor subtypes.
- To highlight recent pharmacological advancements and patent activity up to December 2009.
- To offer an updated overview of antagonists for all seven P2X receptor subtypes.
Main Methods:
- Systematic review of patent literature concerning P2X receptor antagonists.
- Analysis of pharmacological data and recent highlights for each P2X receptor subtype (P2X1R-P2X7R).
- Focus on drug-like antagonists patented within the last four years prior to December 2009.
Main Results:
- An up-to-date overview of patented drug-like antagonists for P2X1R through P2X7R is presented.
- The review covers patent literature up to December 2009, detailing recent pharmacological findings.
- Key developments in P2X receptor antagonist research are highlighted.
Conclusions:
- P2X7 receptor antagonists and other P2X inhibitors are anticipated for therapeutic use in diseases like rheumatoid arthritis.
- Several P2X7 receptor antagonists are progressing through Phase I and II clinical trials.
- The patent landscape indicates significant progress towards P2X receptor-targeted therapeutics.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:15G Protein-coupled Receptors
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.